BRIEF-Biogen And Stoke Therapeutics Enter Into Collaboration

Reuters
18 Feb
BRIEF-Biogen And Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Enter Into Collaboration

Feb 18 (Reuters) - Biogen Inc BIIB.O:

  • BIOGEN AND STOKE THERAPEUTICS ENTER INTO COLLABORATION TO DEVELOP AND COMMERCIALIZE ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME, A RARE GENETIC EPILEPSY ASSOCIATED WITH REFRACTORY SEIZURES AND NEURODEVELOPMENTAL IMPAIRMENTS

  • BIOGEN INC - PHASE 3 STUDY OF ZOREVUNERSEN TO INITIATE IN Q2 2025

  • BIOGEN INC - STOKE RETAINS EXCLUSIVE RIGHTS FOR ZOREVUNERSEN IN US, CANADA, MEXICO; BIOGEN GETS REST OF WORLD

Source text: ID:nBwbh3DmPa

Further company coverage: BIIB.O

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10